阿利吉仑研究进展  

Research Progress of Renin Inhibitor-Aliskiren

作　　者：夏斯桂[1] 马建华[1] 

机构地区：[1]南京医科大学附属南京第一医院内分泌科,南京210012

出　　处：《医学综述》2012年第10期1557-1559,共3页Medical Recapitulate

摘　　要：肾素-血管紧张素-醛固酮系统(RAAS)是一种调节血压及血容量的关键系统。RAAS的过度激活会导致高血压相关的器官损害。肾素抑制剂作用于RAAS的第一限速步骤,抑制该步骤能够提供良好的血压控制及器官保护作用。阿利吉仑是一类新的直接肾素抑制剂,在普通高血压患者中阿利吉仑能够有效地降低血压。同时,阿利吉仑对心脏、肾脏的保护作用被大量临床研究证实。阿利吉仑在老年、肥胖、糖尿病等特殊高血压人群中亦有不错的的降压效果。The reninangiotensin-aldosterone system（RAAS） is a key mediator of blood pressure （BP）and volume regulation. Ovet-stimulation of RAAS also contributes to hypertension-related target organ damages. Renin inhibitor interferes with the first rate-limiting step in RAAS,the inhibition of which is a very attractive target for lowering blood pressure and target-organ protection. Aliskiren, a direct renin inhibitor, is the first example of a novel class of antihypcrtensive drugs with potent antiproteinuric effects. Meanwhile, the protec- tion on the heart and kidney of aliskiren has been proved by a large number of clinical trials. Aliskiren also has a good pressure reduction on the special patient group such as the elderly, obesity and diabetes.

关 键 词：阿利吉仑 肾素-血管紧张素-醛固酮系统 高血压 靶器官保护 

分 类 号：R972.4[医药卫生—药品]